MHRA Approves Lynavoy for Itching in Adults With PBC
On 1 May 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, said it had approved linerixibat, sold as Lynavoy, for adults with primary biliary cholangitis who are dealing with itching linked to the illness. If you do not know much about PBC, this is a good moment to pause, because the story is not just about a new tablet. It is also about how a symptom that can sound small on paper can be exhausting in real life. For many readers, itching may not sound like a major treatment issue. But in PBC it can be persistent, distressing and difficult to shrug off, especially when it affects sleep. That is why this approval matters: the MHRA is saying there is now another treatment option for a very specific problem faced by some adults living with the condition.
Primary biliary cholangitis is a liver disease in which the bile ducts become damaged. As the MHRA explains, that damage can lead to a build-up of bile acids in the blood, and that build-up is thought to be one reason why some patients itch. So this medicine is aimed at symptom relief. It is not presented in the MHRA notice as a cure for PBC itself; it has been approved to help with the itching that comes with it. **What this means:** when you read an approval story like this, it helps to ask one basic question first: what exactly has been approved? In this case, the answer is clear. Lynavoy has been approved for itching in adults with PBC, not as a general treatment for every liver problem and not as a blanket answer for everyone with the condition.
The medicine is taken by mouth as a film-coated tablet, with the recommended dose listed by the MHRA as one tablet twice a day. The approval was granted to GlaxoSmithKline UK Limited, and the notice says the product went through the National Procedure. In plain English, that means the UK regulator reviewed the evidence and decided the benefits were strong enough, on the information available, to allow the medicine to be used for this purpose. That approval is important, but it is not the same as saying the medicine will suit every patient. A medicine can be authorised and still require careful decisions in clinic about who should take it, what other conditions or medicines matter, and which side effects need watching.
The evidence behind this decision came from a global Phase 3 trial called Glisten. This is the part of the story where medicine reporting can become jargon-heavy, so it is worth slowing down. A Phase 3 trial is usually one of the later large tests before or around approval, designed to see whether a treatment works well enough and safely enough in the group it is meant for. In Glisten, 238 patients were randomly assigned to one of two groups for 24 weeks. One group took linerixibat 40 mg twice daily. The other took a placebo, which is a lookalike treatment with no active medicine. Random assignment matters because it helps researchers compare like with like, instead of simply guessing whether improvements happened because of the drug or by chance.
According to the MHRA summary, the results showed that linerixibat reduced itching and also improved sleep disruption caused by that itching. The main measure in the study, called the Monthly Itch Score, improved by a statistically significant amount in the people taking linerixibat compared with those taking placebo. That phrase can sound technical, but the basic idea is simple: the difference was strong enough that researchers judged it unlikely to be down to random variation alone. **What it means for you as a reader:** a Phase 3 success is a strong piece of evidence, but it is not a promise that every single patient will feel the same benefit in the same way. Trial averages tell us about overall effect. Real-world use then adds another layer, because patients differ in symptoms, other illnesses and how they respond to treatment.
The MHRA’s Julian Beach said the approval gives adults with PBC who experience itching a new treatment option, and he also stressed something just as important: monitoring does not stop on approval day. Regulators continue to watch medicines as they are used more widely, because a clinical trial, however well run, cannot capture every possible experience across the whole population. That is where the Yellow Card scheme comes in. The MHRA is asking anyone who suspects a side effect from Lynavoy to speak to their doctor, pharmacist or nurse and report it through Yellow Card, either on the website or through the app. Yellow Card reports are for suspected side effects; they do not by themselves prove a medicine caused a problem. What they do is help safety teams spot patterns early, which is one of the ways medicine regulation carries on after a product reaches patients.
If you are reading this because you or someone you know has PBC, the most practical takeaway is this: there is a newly approved option for itch relief, but the next step is a clinical conversation, not self-diagnosis. Ask what benefit is realistic, how quickly the medicine may work, what side effects to look out for, and how it fits with any other treatment already in place. The MHRA says the full list of reported side effects sits in section 4 of the Patient Information Leaflet, and the Summary of Product Characteristics will be published on the MHRA products website within seven days of approval. There is also a wider lesson here for all of us. Stories about medicine approvals can feel distant or highly technical, yet they are really about evidence, scrutiny and public reporting. This one gives you a clear chain to follow: a condition causes a symptom, a medicine is tested in a Phase 3 trial, a regulator reviews the results, and safety checks continue through systems such as Yellow Card. That is how a treatment moves from trial data into everyday healthcare decision-making.